Diabetes Mellitus and Risk of Hepatocellular Carcinoma

Overview

Journal Biomed Res Int

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
General Medicine

Date 2018 Jan 31

PMID 29379799

Citations 39

Authors

Xu Li

Xiaocong Wang

Pujun Gao

Affiliations

Soon will be listed here.

Abstract

The occurrence of hepatocellular carcinoma (HCC) is two to three times higher in patients with diabetes mellitus (DM), the prevalence of which is increasing sharply worldwide. The purpose of this review was to describe clinical links between DM and HCC and potential biological mechanisms that may account for this association. We evaluated the role of potential pathways that could account for the development of HCC with different etiologies in the presence of DM. In addition, we also briefly discuss the potential effect of other factors such as type and dosage of antidiabetic medicines and duration of DM on HCC risk.

Citing Articles

Innovative Drugs First Implemented in Type 2 Diabetes Mellitus and Obesity and Their Effects on Metabolic Dysfunction-Associated Steatohepatitis (MASH)-Related Fibrosis and Cirrhosis.

Cazac-Panaite G, Lacatusu C, Grigorescu E, Fosalau A, Onofriescu A, Mihai B J Clin Med. 2025; 14(4).

PMID: 40004572 PMC: 11857078. DOI: 10.3390/jcm14041042.

Risk and Prognosis of Hepatocellular Carcinoma in Mexican Americans with Type 2 Diabetes Mellitus.

Hatia R, Hwang L, Li R, Troisi C, Jalal P, Amos C J Hepatocell Carcinoma. 2025; 12:93-106.

PMID: 39867264 PMC: 11762437. DOI: 10.2147/JHC.S477141.

Metformin in Antiviral Therapy: Evidence and Perspectives.

Halabitska I, Petakh P, Lushchak O, Kamyshna I, Oksenych V, Kamyshnyi O Viruses. 2025; 16(12.

PMID: 39772244 PMC: 11680154. DOI: 10.3390/v16121938.

Integrative Network Pharmacology, Molecular Docking, and Dynamics Simulations Reveal the Mechanisms of in Diabetic Nephropathy Treatment: An In Silico Study.

Singh R, Sahu N, Tyagi R, Alam P, Akhtar A, Walia R Curr Issues Mol Biol. 2024; 46(11):11868-11889.

PMID: 39590299 PMC: 11592827. DOI: 10.3390/cimb46110705.

Altered Metabolites in Hepatocellular Carcinoma (HCC) Paving the Road for Metabolomics Signature and Biomarkers for Early Diagnosis of HCC.

Al-Amodi H, Kamel H Cureus. 2024; 16(10):e71968.

PMID: 39569240 PMC: 11576499. DOI: 10.7759/cureus.71968.

References

Yuan J, Govindarajan S, Arakawa K, Yu M . Synergism of alcohol, diabetes, and viral hepatitis on the risk of hepatocellular carcinoma in blacks and whites in the U.S. Cancer. 2004; 101(5):1009-17. DOI: 10.1002/cncr.20427. View

Palakurthi S, Aktas H, Grubissich L, Mortensen R, Halperin J . Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor gamma and mediated by inhibition of translation initiation. Cancer Res. 2001; 61(16):6213-8. View

Bruix J, Sherman M . Management of hepatocellular carcinoma: an update. Hepatology. 2011; 53(3):1020-2. PMC: 3084991. DOI: 10.1002/hep.24199. View

La Vecchia C . Diabetes mellitus, medications for type 2 diabetes mellitus, and cancer risk. Metabolism. 2011; 60(10):1357-8. DOI: 10.1016/j.metabol.2011.03.011. View

Niedernhofer L, Daniels J, Rouzer C, Greene R, Marnett L . Malondialdehyde, a product of lipid peroxidation, is mutagenic in human cells. J Biol Chem. 2003; 278(33):31426-33. DOI: 10.1074/jbc.M212549200. View

Ondrey F . Peroxisome proliferator-activated receptor gamma pathway targeting in carcinogenesis: implications for chemoprevention. Clin Cancer Res. 2009; 15(1):2-8. DOI: 10.1158/1078-0432.CCR-08-0326. View

Nakagawa H, Maeda S, Yoshida H, Tateishi R, Masuzaki R, Ohki T . Serum IL-6 levels and the risk for hepatocarcinogenesis in chronic hepatitis C patients: an analysis based on gender differences. Int J Cancer. 2009; 125(10):2264-9. DOI: 10.1002/ijc.24720. View

Warburg O . On the origin of cancer cells. Science. 1956; 123(3191):309-14. DOI: 10.1126/science.123.3191.309. View

Lok A, Lai C, Wu P, Wong V, Yeoh E, Lin H . Hepatitis B virus infection in Chinese families in Hong Kong. Am J Epidemiol. 1987; 126(3):492-9. DOI: 10.1093/oxfordjournals.aje.a114681. View

10.

Donadon V, Balbi M, Valent F, Avogaro A . Glycated hemoglobin and antidiabetic strategies as risk factors for hepatocellular carcinoma. World J Gastroenterol. 2010; 16(24):3025-32. PMC: 2890943. DOI: 10.3748/wjg.v16.i24.3025. View

11.

Lin H, Yang S, Chuckaree C, Kuhajda F, Ronnet G, Diehl A . Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med. 2000; 6(9):998-1003. DOI: 10.1038/79697. View

12.

Moore M, Park C, Tsuda H . Implications of the hyperinsulinaemia-diabetes-cancer link for preventive efforts. Eur J Cancer Prev. 1998; 7(2):89-107. View

13.

Butt A, Khan U, McGinnis K, Skanderson M, Kwoh C . Co-morbid medical and psychiatric illness and substance abuse in HCV-infected and uninfected veterans. J Viral Hepat. 2007; 14(12):890-6. DOI: 10.1111/j.1365-2893.2007.00885.x. View

14.

Lai S, Chen P, Liao K, Muo C, Lin C, Sung F . Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study. Am J Gastroenterol. 2011; 107(1):46-52. DOI: 10.1038/ajg.2011.384. View

15.

Chen C, Chen J, Wang J, Chang K, Tseng P, Kee K . Diabetes mellitus, metabolic syndrome and obesity are not significant risk factors for hepatocellular carcinoma in an HBV- and HCV-endemic area of Southern Taiwan. Kaohsiung J Med Sci. 2013; 29(8):451-9. DOI: 10.1016/j.kjms.2012.12.006. View

16.

Giovannucci E, Harlan D, Archer M, Bergenstal R, Gapstur S, Habel L . Diabetes and cancer: a consensus report. CA Cancer J Clin. 2010; 60(4):207-21. DOI: 10.3322/caac.20078. View

17.

Adami H, Chow W, Nyren O, Berne C, Linet M, Ekbom A . Excess risk of primary liver cancer in patients with diabetes mellitus. J Natl Cancer Inst. 1996; 88(20):1472-7. DOI: 10.1093/jnci/88.20.1472. View

18.

Schlesinger S, Aleksandrova K, Pischon T, Jenab M, Fedirko V, Trepo E . Diabetes mellitus, insulin treatment, diabetes duration, and risk of biliary tract cancer and hepatocellular carcinoma in a European cohort. Ann Oncol. 2013; 24(9):2449-55. PMC: 3755330. DOI: 10.1093/annonc/mdt204. View

19.

Thakkar B, Aronis K, Vamvini M, Shields K, Mantzoros C . Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies. Metabolism. 2013; 62(7):922-34. DOI: 10.1016/j.metabol.2013.01.014. View

20.

Tanaka K, Tsuji I, Tamakoshi A, Matsuo K, Wakai K, Nagata C . Diabetes mellitus and liver cancer risk: an evaluation based on a systematic review of epidemiologic evidence among the Japanese population. Jpn J Clin Oncol. 2014; 44(10):986-99. DOI: 10.1093/jjco/hyu108. View